{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:40:08Z","timestamp":1789760408103,"version":"4.0.1"},"reference-count":199,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.pbb.2024.173895","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:48:03Z","timestamp":1729788483000},"page":"173895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Nonsedating anxiolytics"],"prefix":"10.1016","volume":"245","author":[{"given":"Rok","family":"Cerne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Chrzanowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Lippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2024.173895_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7399","article-title":"Patterns in outpatient benzodiazepine prescribing in the United States","volume":"2","author":"Agarwal","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.pbb.2024.173895_bb0010","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/j.bja.2018.12.006","article-title":"Analgesic potential of PF-06372865, an \u03b12\/\u03b13\/\u03b15 subtype-selective GABAA partial agonist, in humans","volume":"123","author":"van Amerongen","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.pbb.2024.173895_bb7030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/ADM.0000000000000350","article-title":"A review of alprazolam use, misuse, and withdrawal","volume":"12","author":"Ait-Daoud","year":"2018","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.pbb.2024.173895_bb0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1054-3589(08)57004-9","article-title":"Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023","volume":"57","author":"Atack","year":"2009","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/7854_2009_30","article-title":"GABAA receptor alpha2\/alpha3 subtype-selective modulators as potential nonsedating anxiolytics","volume":"2","author":"Atack","year":"2010","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2024.173895_bb0025","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2174\/156802611795371350","article-title":"GABAA receptor subtype-selective modulators. I. \u03b12\/\u03b13-selective agonists as non-sedating anxiolytics","volume":"11","author":"Atack","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0030","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.105.089920","article-title":"TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates","volume":"316","author":"Atack","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb7040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1124\/jpet.109.157909","article-title":"Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans","volume":"332","author":"Atack","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb7035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0269881109354928","article-title":"Preclinical and clinical pharmacology of TPA023B, a GABAA receptor &alpha;2\/&alpha;3 subtype-selective partial agonist","volume":"25","author":"Atack","year":"2011","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.pbb.2024.173895_bb0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/0269881109354927","article-title":"MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans","volume":"25","author":"Atack","year":"2011","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.pbb.2024.173895_bb0050","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2147\/NDT.S185757","article-title":"Selective serotonin reuptake inhibitor-induced sexual dysfunction: current management perspectives","volume":"16","author":"Atmaca","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pbb.2024.173895_bb0055","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0376-8716(03)00099-1","article-title":"Principles of drug abuse liability assessment in laboratory animals","volume":"70","author":"Ator","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pbb.2024.173895_bb7045","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/jpet.109.158303","article-title":"Reducing abuse liability of GABAA\/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2\/3 subtypes","volume":"332","author":"Ator","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0070","author":"Avenue Therapeutics"},{"key":"10.1016\/j.pbb.2024.173895_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d1199","article-title":"Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis","volume":"342","author":"Baldwin","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.pbb.2024.173895_bb0080","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1360-0443.1991.tb01747.x","article-title":"Drug abuse potential evaluation in animals","volume":"86","author":"Balster","year":"1991","journal-title":"Br. J. Addict."},{"issue":"7","key":"10.1016\/j.pbb.2024.173895_bb0085","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1177\/10600280231204953","article-title":"Zuranolone: the first FDA-approved oral treatment option for postpartum depression","volume":"58","author":"Barnes","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pbb.2024.173895_bb0090","first-page":"1129","article-title":"Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal","volume":"18","author":"Baty","year":"1994","journal-title":"Gastroenterol. Clin. Biol."},{"key":"10.1016\/j.pbb.2024.173895_bb0095","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.j.pain.0000460331.33385.e8","article-title":"GABAergic modulation in central sensitization in humans: a randomized placebo-controlled pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers","volume":"156","author":"Besson","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.pbb.2024.173895_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172996","article-title":"The \u03b12,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development","volume":"196","author":"Biggerstaff","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0105","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/00004583-199409000-00009","article-title":"Fluoxetine for childhood anxiety disorders","volume":"33","author":"Birmaher","year":"1994","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0110","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/bmj.280.6218.910","article-title":"Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the review of medicines","volume":"280","author":"BMJ","year":"1980","journal-title":"Br. Med. J."},{"key":"10.1016\/j.pbb.2024.173895_bb0115","author":"Boston University"},{"key":"10.1016\/j.pbb.2024.173895_bb0120","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1073\/pnas.74.9.3805","article-title":"Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding","volume":"74","author":"Braestrup","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2024.173895_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(97)00096-4","article-title":"The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABAA receptors","volume":"325","author":"Brot","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0130","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.mp.4001852","article-title":"Treatment-resistant anxiety disorders","volume":"11","author":"Bystritsky","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0135","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1021\/jm058034a","volume":"48","author":"Carling","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0140","doi-asserted-by":"crossref","unstructured":"Castellano D, Shepard RD, Lu W (2021) Looking for novelty in an \u201cold\u201d receptor: recent advances toward our understanding of GABAARs and their implications in receptor pharmacology. Front. Neurosci. 14 doi:https:\/\/doi.org\/10.3389\/fnins.2020.616298 [Accessed April 20, 2022].","DOI":"10.3389\/fnins.2020.616298"},{"key":"10.1016\/j.pbb.2024.173895_bb0145","series-title":"A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder. clinicaltrials.gov","author":"Cerevel Therapeutics, LLC","year":"2024"},{"issue":"1","key":"10.1016\/j.pbb.2024.173895_bb0150","first-page":"117","article-title":"Improvements in the pharmacological profile of diazepam by KRM-II-81, an imidizodiazepine positive allosteric modulator of alpha2\/3-containing GABAA receptors: preclinical data predict enhanced efficacy for epilepsy, chronic pain, anxiety, and depression","volume":"2","author":"Cerne","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.pbb.2024.173895_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108035","article-title":"GABAkines \u2013 advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors","volume":"234","author":"Cerne","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0160","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/bcp.12413","article-title":"The central nervous system effects of the partial GABA-A\u03b12,3-selective receptor modulator AZD7325 in comparison with lorazepam in healthy males","volume":"78","author":"Chen","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2016.12.009","article-title":"Effects of the synthetic neurosteroid ganaxolone on seizure activity and behavioral deficits in an Angelman syndrome mouse model","volume":"116","author":"Ciarlone","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2024.173895_bb0170","article-title":"A review of the updated pharmacophore for the alpha 5 GABA(A) benzodiazepine receptor model","volume":"2015","author":"Clayton","year":"2015","journal-title":"Int. J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0175","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/YCO.0b013e32831a473d","article-title":"Current use of benzodiazepines in anxiety disorders","volume":"22","author":"Cloos","year":"2009","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0180","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1523\/JNEUROSCI.22-13-05572.2002","article-title":"Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor","volume":"22","author":"Collinson","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2024.173895_bb0185","author":"Cook"},{"key":"10.1016\/j.pbb.2024.173895_bb0190","author":"Cook"},{"key":"10.1016\/j.pbb.2024.173895_bb0195","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/arclin\/acx120","article-title":"The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis","volume":"33","author":"Crowe","year":"2018","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.pbb.2024.173895_bb0200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1755-5949.2009.00109.x","article-title":"A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorder","volume":"16","author":"Czobor","year":"2010","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0205","author":"Dasse"},{"key":"10.1016\/j.pbb.2024.173895_bb0210","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1124\/jpet.105.092320","article-title":"An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition","volume":"316","author":"Dawson","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0215","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial","volume":"78","author":"Deligiannidis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0220","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14475","article-title":"Effect of Zuranolone on concurrent anxiety and insomnia symptoms in women with postpartum depression","volume":"84","author":"Deligiannidis","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0225","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.neuropharm.2010.11.026","article-title":"HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain","volume":"60","author":"Di Lio","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2024.173895_bb0230","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1523\/JNEUROSCI.1166-05.2005","article-title":"Evidence for a significant role of \u03b13-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines","volume":"25","author":"Dias","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2024.173895_bb0235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/jpet.118.249250","article-title":"Evidence that sedative effects of benzodiazepines involve unexpected GABAA receptor subtypes: quantitative observation studies in Rhesus monkeys","volume":"366","author":"Duke","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0240","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cns.13046","article-title":"Pronounced antiepileptic activity of the subtype-selective GABAA-positive allosteric modulator PF-06372865 in the GAERS absence epilepsy model","volume":"25","author":"Duveau","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0245","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.tips.2018.04.003","article-title":"An emerging circuit pharmacology of GABAA receptors","volume":"39","author":"Engin","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2024.173895_bb0250","author":"Engrail.com"},{"key":"10.1016\/j.pbb.2024.173895_bb0255","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/14737175.2023.2211767","article-title":"Pharmacological treatment of generalised anxiety disorder: current practice and future directions","volume":"23","author":"Fagan","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.pbb.2024.173895_bb0260","author":"FDA-CDER"},{"key":"10.1016\/j.pbb.2024.173895_bb0265","author":"Federal Register"},{"key":"10.1016\/j.pbb.2024.173895_bb0270","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.neuropharm.2010.08.011","article-title":"Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure","volume":"59","author":"Fischer","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2024.173895_bb0275","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainresbull.2017.03.001","article-title":"Pharmacological and antihyperalgesic properties of the novel \u03b12\/3 preferring GABAA receptor ligand MP-III-024","volume":"131","author":"Fischer","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pbb.2024.173895_bb0280","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-019-00605-7","article-title":"Pharmacotherapy of postpartum depression: current approaches and novel drug development","volume":"33","author":"Frieder","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2024.173895_bb0285","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-2999(99)00013-8","article-title":"Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans","volume":"368","author":"Fujita","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0290","article-title":"Antidepressant and benzodiazepine for major depression","author":"Furukawa","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pbb.2024.173895_bb0295","first-page":"222","article-title":"Pharmacotherapy of anxiety disorders: current and emerging treatment options","volume":"19","author":"Garakani","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0300","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-6147(99)01318-8","article-title":"Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders","volume":"20","author":"Gasior","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2024.173895_bb0305","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1124\/jpet.109.161885","article-title":"Limiting activity at \u03b21-subunit-containing GABAA receptor subtypes reduces Ataxia","volume":"332","author":"Gee","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0310","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/jwh.2020.8483","article-title":"Brexanolone in postpartum depression: post hoc analyses to help inform clinical decision-making","volume":"30","author":"Gerbasi","year":"2021","journal-title":"J. Womens Health (Larchmt)"},{"key":"10.1016\/j.pbb.2024.173895_bb0315","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/oby.22969","article-title":"Antidepressant medications and weight change: a narrative review","volume":"28","author":"Gill","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.pbb.2024.173895_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.625233","article-title":"8-substituted triazolobenzodiazepines: in vitro and in vivo pharmacology in relation to structural docking at the \u03b11 subunit-containing GABAA receptor","volume":"12","author":"Golani","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2024.173895_bb0325","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/bdd.2313","article-title":"Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the \u03b12\/3-selective GABAkine KRM-II-81","volume":"43","author":"Golani","year":"2022","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.pbb.2024.173895_bb0330","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","article-title":"Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review","volume":"19","author":"Gomez","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.pbb.2024.173895_bb0335","first-page":"435","article-title":"Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences","volume":"293","author":"Greenblatt","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0340","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00004714-199008000-00002","article-title":"Relative abuse liability of different benzodiazepines in drug abusers","volume":"10","author":"Griffiths","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0345","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1007\/s00213-016-4369-8","article-title":"Benzodiazepine and neuroactive steroid combinations in rats: anxiolytic-like and discriminative stimulus effects","volume":"233","author":"Gunter","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2024.173895_bb0350","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1212\/WNL.0000000000007271","article-title":"Photosensitive epilepsy: robust clinical efficacy of a selective GABA potentiator","volume":"92","author":"Gurrell","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2024.173895_bb0355","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0269881106072343","article-title":"Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers","volume":"21","author":"de Haas","year":"2007","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.pbb.2024.173895_bb0360","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0269881107082108","article-title":"Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers","volume":"22","author":"de Haas","year":"2008","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.pbb.2024.173895_bb0365","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0269881111415731","article-title":"The effects of TPA023, a GABAA\u03b12,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol","volume":"26","author":"de Haas","year":"2012","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.pbb.2024.173895_bb0370","series-title":"Adverse Syndromes and Psychiatric Drugs: A Clinical Guide","author":"Haddad","year":"2004"},{"key":"10.1016\/j.pbb.2024.173895_bb0375","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF00449811","article-title":"Pharmacology of the benzodiazepine receptor","volume":"238","author":"Haefely","year":"1989","journal-title":"Eur. Arch. Psychiatr. Neurol. Sci."},{"key":"10.1016\/j.pbb.2024.173895_bb0380","first-page":"131","article-title":"Pharmacophore\/receptor models for GABA(A)\/BzR \u03b12\u03b23\u03b32, \u03b13\u03b23\u03b32 and \u03b14\u03b23\u03b32 recombinant subtypes. Included volume analysis and comparison to \u03b11\u03b23\u03b32, \u03b15\u03b23\u03b32, and \u03b16\u03b23\u03b32 subtypes","volume":"17","author":"He","year":"2000","journal-title":"Drug Des. Discov."},{"key":"10.1016\/j.pbb.2024.173895_bb0385","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02741459","article-title":"The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes","volume":"18","author":"Hevers","year":"1998","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.pbb.2024.173895_bb0390","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.2020.22106","article-title":"Balancing the risks and benefits of benzodiazepines","volume":"325","author":"Hirschtritt","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2024.173895_bb0395","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuroscience.2013.01.008","article-title":"Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain","volume":"236","author":"H\u00f6rtnagl","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2024.173895_bb0400","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1021\/jm980317y","volume":"41","author":"Huang","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0405","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1113\/jphysiol.2006.106617","article-title":"Fast IPSCs in rat thalamic reticular nucleus require the GABAA receptor beta1 subunit","volume":"572","author":"Huntsman","year":"2006","journal-title":"J. Physiol."},{"key":"10.1016\/j.pbb.2024.173895_bb0410","doi-asserted-by":"crossref","first-page":"41438","DOI":"10.1074\/jbc.M205645200","article-title":"The beta subunit determines the ion selectivity of the GABAA receptor","volume":"277","author":"Jensen","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0415","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jama.292.3.338","article-title":"Antidepressants and the risk of suicidal behaviors","volume":"292","author":"Jick","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.pbb.2024.173895_bb0420","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/j.pain.0000000000001392","article-title":"Positive allosteric modulators of nonbenzodiazepine \u03b3-aminobutyric acidA receptor subtypes for the treatment of chronic pain","volume":"160","author":"Johnstone","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.pbb.2024.173895_bb0425","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02244836","article-title":"Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: an analysis based on fractional receptor occupancies","volume":"114","author":"Jones","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2024.173895_bb0430","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00213-016-4506-4","article-title":"GABAA receptor occupancy by subtype selective GABAA\u03b12,3 modulators: PET studies in humans","volume":"234","author":"Jucaite","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2024.173895_bb0435","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2024.173895_bb0440","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/(SICI)1520-6394(1996)4:6<257::AID-DA1>3.0.CO;2-9","article-title":"Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs","volume":"4","author":"Katz","year":"1996","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pbb.2024.173895_bb0445","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb7050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1017\/S2045796015000189","article-title":"Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys","volume":"24","author":"Kessler","year":"2015","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.pbb.2024.173895_bb0455","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-020-2654-5","article-title":"Shared structural mechanisms of general anaesthetics and benzodiazepines","volume":"585","author":"Kim","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2024.173895_bb0460","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1176\/appi.ajp.2020.20020134","article-title":"Understanding the clinical effects and mechanisms of action of neurosteroids","volume":"178","author":"Kleinman","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0465","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0091-3057(79)90125-4","article-title":"Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors","volume":"11","author":"Klepner","year":"1979","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0470","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Knight","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pbb.2024.173895_bb0475","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1021\/acschemneuro.0c00295","article-title":"Imidazodiazepine anticonvulsant, KRM-II-81, produces novel, non-diazepam-like Antiseizure effects","volume":"11","author":"Knutson","year":"2020","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.pbb.2024.173895_bb0480","doi-asserted-by":"crossref","first-page":"423","DOI":"10.31887\/DCNS.2011.13.4\/nkoen","article-title":"Pharmacotherapy of anxiety disorders: a critical review","volume":"13","author":"Koen","year":"2011","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.pbb.2024.173895_bb0485","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pbb.2008.02.019","article-title":"Novel discriminative stimulus effects of TPA023B, subtype-selective gamma-aminobutyric-acid(A)\/benzodiazepine modulator: comparisons with zolpidem, lorazepam, and TPA023","volume":"90","author":"Kohut","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0490","first-page":"471","article-title":"Comparative studies on antidepressant action of alprazolam in different animal models","volume":"38","author":"Kostowski","year":"1986","journal-title":"Pol. J. Pharmacol. Pharm."},{"key":"10.1016\/j.pbb.2024.173895_bb0495","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0924-977X(92)90081-I","article-title":"The selectivity of zolpidem and alpidem for the \u03b11-subunit of the GABAA receptor","volume":"2","author":"Langer","year":"1992","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0500","series-title":"Characterization of Novel \u03b12\/\u03b13 Subtype-Selective GABAA Receptor Positive Allosteric Modulators","author":"Lewter","year":"2019"},{"key":"10.1016\/j.pbb.2024.173895_bb0505","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/acschemneuro.6b00447","article-title":"Antinociceptive effects of a novel \u03b12\/\u03b13 subtype selective GABAA receptor positive allosteric modulator","volume":"8","author":"Lewter","year":"2017","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.pbb.2024.173895_bb7055","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1055\/s-0037-1610211","article-title":"Improved synthesis of anxiolytic, anticonvulsant, and antinociceptive \u03b12\/\u03b13-GABA(A)-ergic receptor subtype selective ligands as promising agents to treat anxiety, epilepsy, and neuropathic pain","volume":"50","author":"Li","year":"2018","journal-title":"Synthesis"},{"key":"10.1016\/j.pbb.2024.173895_bb0510","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.lfs.2005.08.002","article-title":"Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying","volume":"78","author":"Li","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2024.173895_bb0515","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00213-008-1401-7","article-title":"Contribution of alpha1 subunit-containing gamma-aminobutyric acidA (GABAA) receptors to motor-impairing effects of benzodiazepines in squirrel monkeys","volume":"203","author":"Licata","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2024.173895_bb0520","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2014.12101342","article-title":"Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder","volume":"171","author":"Liebowitz","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0525","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/da.22546","article-title":"Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder","volume":"33","author":"Liebowitz","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pbb.2024.173895_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102308","article-title":"Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses","volume":"66","author":"Lin","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.pbb.2024.173895_bb0535","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1073\/pnas.0502579102","article-title":"Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator","volume":"102","author":"Lippa","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2024.173895_bb0540","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0091-3057(78)90368-4","article-title":"Relationship between benzodiazepine receptors and experimental anxiety in rats","volume":"9","author":"Lippa","year":"1978","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0545","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0091-3057(79)90304-6","article-title":"A synthetic non-benzodiazepine ligand for benzodiazepine receptors: a probe for investigating neuronal substrates of anxiety","volume":"11","author":"Lippa","year":"1979","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0550","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/0024-3205(82)90001-7","article-title":"Molecular substrates of anxiety: clues from the heterogeneity of benzodiazepine receptors","volume":"31","author":"Lippa","year":"1982","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2024.173895_bb0555","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1021\/jm950887n","article-title":"Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABAA receptors","volume":"39","author":"Liu","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0560","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1126\/science.290.5489.131","article-title":"Molecular and neuronal substrate for the selective attenuation of anxiety","volume":"290","author":"L\u00f6w","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pbb.2024.173895_bb0565","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1021\/acs.jmedchem.9b01312","article-title":"Subtype selective \u03b3-aminobutyric acid type a receptor (GABAAR) modulators acting at the benzodiazepine binding site: an update","volume":"63","author":"Maramai","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0570","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007139.pub2","article-title":"Alprazolam for depression","author":"van Marwijk","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pbb.2024.173895_bb0575","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/ejp.1554","article-title":"GABAergic modulation of secondary hyperalgesia: a randomized controlled 4-way crossover trial with the \u03b12-subunit preferring GABA positive allosteric modulator, N-desmethyl-clobazam in healthy volunteers","volume":"24","author":"Matthey","year":"2020","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.pbb.2024.173895_bb0580","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1176\/appi.ps.201800321","article-title":"Benzodiazepine use and misuse among adults in the United States","volume":"70","author":"Maust","year":"2019","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.pbb.2024.173895_bb0585","article-title":"Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the national survey on drug use and health","volume":"14","author":"McHugh","year":"2023","journal-title":"Front. Psych."},{"key":"10.1016\/j.pbb.2024.173895_bb0590","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.pbb.2024.173895_bb0595","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2024.173895_bb0600","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pbb.2018.04.009","article-title":"An antidepressant-related pharmacological signature for positive allosteric modulators of \u03b12\/3-containing GABAA receptors","volume":"170","author":"Methuku","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0605","doi-asserted-by":"crossref","first-page":"27550","DOI":"10.1021\/acsomega.2c03029","article-title":"Hydrochloride salt of the GABAkine KRM-II-81","volume":"7","author":"Mian","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.pbb.2024.173895_bb0610","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1192\/bjp.179.6.514","article-title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial","volume":"179","author":"Michelson","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0615","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/FBP.0000000000000464","article-title":"Effects of the \u03b12\/\u03b13-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam","volume":"30","author":"Moerke","year":"2019","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105236","article-title":"Distinct neurodevelopmental and epileptic phenotypes associated with gain- and loss-of-function GABRB2 variants","volume":"106","author":"Mohammadi","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pbb.2024.173895_bb0625","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/00926239708403923","article-title":"SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients","volume":"23","author":"Montejo-Gonz\u00e1lez","year":"1997","journal-title":"J. Sex Marital Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0630","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0091-3057(88)90211-0","article-title":"Clinical studies with the new anxiolytic alpidem in anxious patients: an overview of the European experiences","volume":"29","author":"Musch","year":"1988","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0635","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0014-2999(87)90648-0","article-title":"The effect of agonists at the GABA-benzodiazepine receptor complex on the duration of immobility of mice in the forced swimming test","volume":"142","author":"Nagatani","year":"1987","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0640","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bmc.2012.10.057","article-title":"Search for \u03b13\u03b2\u2082\/\u2083\u03b32 subtype selective ligands that are stable on human liver microsomes","volume":"21","author":"Namjoshi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0645","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1124\/pr.112.007419","article-title":"Intracranial self-stimulation to evaluate abuse potential of drugs","volume":"66","author":"Negus","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2024.173895_bb0650","author":"Newport"},{"key":"10.1016\/j.pbb.2024.173895_bb0655","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.pbb.2024.173895_bb0660","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.neuron.2018.03.046","article-title":"The GABAA receptor \u03b2 subunit is required for inhibitory transmission","volume":"98","author":"Nguyen","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.pbb.2024.173895_bb0665","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bph.14119","article-title":"Pharmacology in translation: the preclinical and early clinical profile of the novel \u03b12\/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865","volume":"175","author":"Nickolls","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0670","author":"NIMH"},{"key":"10.1016\/j.pbb.2024.173895_bb0675","author":"NIMH"},{"key":"10.1016\/j.pbb.2024.173895_bb0680","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2024.173895_bb0685","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","article-title":"Benzodiazepine use in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0690","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2008.07.045","article-title":"GABA a receptors: subtypes provide diversity of function and pharmacology","volume":"56","author":"Olsen","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2024.173895_bb0695","first-page":"5773","article-title":"Design and identification of a novel, functionally subtype selective GABAA positive allosteric modulator (PF-06372865)","volume":"62","author":"Owen","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0700","doi-asserted-by":"crossref","first-page":"242","DOI":"10.24820\/ark.5550190.p011.398","article-title":"Design, synthesis and characterization of novel gamma-aminobutyric acid type a receptor ligands","volume":"2020","author":"Pandey","year":"2020","journal-title":"ARKIVOC"},{"key":"10.1016\/j.pbb.2024.173895_bb0705","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.122.001362","article-title":"Structural analogs of the GABAkine (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-\u03b1 ] [1,4]diazepin-3-yl) oxazole) (KRM-II-81) are orally bioavailable anticonvulsants without sedation","author":"Pandey","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0710","author":"Peltier"},{"key":"10.1016\/j.pbb.2024.173895_bb0715","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00004714-200102000-00008","article-title":"Augmentation of fluoxetine\u2019s antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors","volume":"21","author":"P\u00e9rez","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pbb.2024.173895_bb0720","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ddr.22042","article-title":"Comparative anticonvulsant activity of the GABAkine KRM-II-81 and a deuterated analog","volume":"84","author":"Ping","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.pbb.2024.173895_bb0725","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0306-4522(00)00442-5","article-title":"GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain","volume":"101","author":"Pirker","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2024.173895_bb0730","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1021\/acs.jmedchem.6b01332","article-title":"Synthesis and characterization of a novel gamma-aminobutyric acid type A (GABAA) receptor ligand that combines outstanding metabolic stability, pharmacokinetics, and anxiolytic efficacy","volume":"59","author":"Poe","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0735","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1060028019873320","article-title":"Brexanolone (Zulresso): finally, an FDA-approved treatment for postpartum depression","volume":"54","author":"Powell","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.pbb.2024.173895_bb0740","author":"Praxis Precision Medicines"},{"key":"10.1016\/j.pbb.2024.173895_bb0745","author":"Praxis Precision Medicines"},{"key":"10.1016\/j.pbb.2024.173895_bb0750","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00213-021-05791-1","article-title":"Synergistic antihyperalgesic and antinociceptive effects of morphine and methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024): a positive allosteric modulator at \u03b12GABAA and \u03b13GABAA receptors","volume":"238","author":"Rahman","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2024.173895_bb0755","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1038\/ncomms7803","article-title":"Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype","volume":"6","author":"Ralvenius","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pbb.2024.173895_bb0760","author":"Ralvenius"},{"key":"10.1016\/j.pbb.2024.173895_bb0765","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00213-017-4649-y","article-title":"A randomized controlled trial of ganaxolone in posttraumatic stress disorder","volume":"234","author":"Rasmusson","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2024.173895_bb0770","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yebeh.2018.02.020","article-title":"Role of \u03b22\/3-specific GABA-A receptor isoforms in the development of hippocampus kindling epileptogenesis","volume":"82","author":"Reddy","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0775","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/jm801652d","article-title":"Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models","volume":"52","author":"Rivas","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0780","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/01.nmd.0000198140.02154.32","article-title":"Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients","volume":"194","author":"Rodriguez","year":"2006","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.pbb.2024.173895_bb0785","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrd3502","article-title":"Beyond classical benzodiazepines: novel therapeutic potential of GABA A receptor subtypes","volume":"10","author":"Rudolph","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pbb.2024.173895_bb0790","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev-pharmtox-011613-135947","article-title":"GABAA receptor subtypes: therapeutic potential in down syndrome, affective disorders, schizophrenia, and autism","volume":"54","author":"Rudolph","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pbb.2024.173895_bb0795","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2024.173895_bb0800","first-page":"693","article-title":"Anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. Comparison of diazepam, bretazenil and abecarnil","volume":"275","author":"Rundfeldt","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb7060","series-title":"Sci Rep","first-page":"6242","article-title":"Characterization of zebrafish GABAA receptor subunits","volume":"11","author":"Sadamitsu","year":"2021"},{"key":"10.1016\/j.pbb.2024.173895_bb0805","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","article-title":"GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam","volume":"26","author":"Sankar","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pbb.2024.173895_bb7065","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.pnpbp.2010.01.004","article-title":"Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats?","volume":"34","author":"Savi\u0107","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0810","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1111\/jvim.15955","article-title":"Imepitoin for treatment of idiopathic head tremor syndrome in dogs: a randomized, blinded, placebo-controlled study","volume":"34","author":"Schneider","year":"2020","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.pbb.2024.173895_bb0815","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1007\/s00213-017-4615-8","article-title":"Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats","volume":"234","author":"Schwienteck","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2024.173895_bb0820","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/acschemneuro.3c00555","volume":"15","author":"Sharmin","year":"2024","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.pbb.2024.173895_bb0825","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1192\/bjp.2020.164","article-title":"Benzodiazepines: it\u2019s time to return to the evidence","volume":"218","author":"Silberman","year":"2021","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0830","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/JCP.0000000000000997","volume":"39","author":"Simen","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0835","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tips.2012.08.003","article-title":"Anxioselective anxiolytics: on a quest for the holy grail","volume":"33","author":"Skolnick","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2024.173895_bb0840","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(18)31793-8","article-title":"Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis","volume":"393","author":"Slee","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2024.173895_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e23752","article-title":"KRM\u2013II\u201381 suppresses epileptifom activity across the neural network of cortical tissue from a patient with pharmacoresistant epilepsy","volume":"10","author":"Smith","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.pbb.2024.173895_bb0850","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pbb.2024.173895_bb0855","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12916-017-0889-2","article-title":"The cross-national epidemiology of social anxiety disorder: data from the world mental health survey initiative","volume":"15","author":"Stein","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.pbb.2024.173895_bb0860","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41586-023-06556-w","article-title":"Cryo-EM structures reveal native GABAA receptor assemblies and pharmacology","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2024.173895_bb0865","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nature08758","article-title":"Neural bases for addictive properties of benzodiazepines","volume":"463","author":"Tan","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2024.173895_bb0870","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/070674370505000702","article-title":"Listening to the past: history, psychiatry, and anxiety","volume":"50","author":"Tone","year":"2005","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.pbb.2024.173895_bb0875","series-title":"The Age of Anxiety: A History of America\u2019s Turbulent Affair with Tranquilizers","author":"Tone","year":"2009"},{"key":"10.1016\/j.pbb.2024.173895_bb0880","first-page":"337","article-title":"Characterization of the anxiolytic properties of a novel neuroactive steroid, Co 2-6749 (GMA-839; WAY-141839; 3\u03b1, 21-dihydroxy-3\u03b2-trifluoromethyl-19-nor-5\u03b2-pregnan-20-one), a selective modulator of \u03b3-aminobutyric acid(A) receptors","volume":"295","author":"Vanover","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0885","article-title":"Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators?","volume":"2012","author":"Vinkers","year":"2012","journal-title":"Adv. Pharmacol. Sci."},{"key":"10.1016\/j.pbb.2024.173895_bb0890","author":"VistaGen Therapeutics, Inc."},{"key":"10.1016\/j.pbb.2024.173895_bb0895","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coph.2004.08.006","article-title":"GABAA receptor subtypes: any clues to the mechanism of benzodiazepine dependence?","volume":"5","author":"Wafford","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0900","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.2147\/DDDT.S240856","article-title":"Review of allopregnanolone agonist therapy for the treatment of depressive disorders","volume":"15","author":"Walkery","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0905","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/epi4.12907","article-title":"Safety and effectiveness of diazepam nasal spray in male and female patients: Post hoc analysis of data from a phase 3 safety study","volume":"9","author":"Wheless","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.pbb.2024.173895_bb0910","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0021-9258(18)45961-3","article-title":"A single histidine in GABAA receptors is essential for benzodiazepine agonist binding","volume":"267","author":"Wieland","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pbb.2024.173895_bb0915","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.1990.tb03616.x","article-title":"Respiratory and sedative effects of clobazam and clonazepam in volunteers","volume":"29","author":"Wildin","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0920","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/275551a0","article-title":"Labelling of benzodiazepine receptors in vivo","volume":"275","author":"Williamson","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2024.173895_bb7070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pbb.2019.02.013","article-title":"The \u03b12,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats","volume":"180","author":"Witkin","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0925","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pbb.2017.04.009","article-title":"Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for \u03b12\/3-containing GABAA receptors","volume":"157","author":"Witkin","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0930","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neuropharm.2018.05.006","article-title":"Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: improved bioavailability enhances anticonvulsant efficacy","volume":"137","author":"Witkin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2024.173895_bb0945","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/jpet.119.260968","article-title":"The positive allosteric modulator of \u03b12\/3-containing GABAA receptors, KRM-II-81, is active in Pharmaco-resistant models of epilepsy and reduces hyperexcitability after traumatic brain injury","volume":"372","author":"Witkin","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2024.173895_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173321","article-title":"The imidazodiazepine, KRM-II-81: an example of a newly emerging generation of GABAkines for neurological and psychiatric disorders","volume":"213","author":"Witkin","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2024.173895_bb0955","series-title":"Advances in Health and Disease","first-page":"163","article-title":"Chapter 5. Better than Xanax","author":"Witkin","year":"2022"},{"key":"10.1016\/j.pbb.2024.173895_bb0960","first-page":"151","article-title":"Benzodiazepines: use, abuse, and consequences","volume":"44","author":"Woods","year":"1992","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.pbb.2024.173895_bb0965","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0269881113507643","article-title":"Limited central side effects of a \u03b2-subunit subtype-selective GABAA receptor allosteric modulator","volume":"28","author":"Yoshimura","year":"2014","journal-title":"J. Psychopharmacol. (Oxford)"},{"key":"10.1016\/j.pbb.2024.173895_bb0970","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.apha.2014.11.007","article-title":"Restoring the spinal pain gate: GABA(A) receptors as targets for novel analgesics","volume":"73","author":"Zeilhofer","year":"2015","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.pbb.2024.173895_bb0975","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41586-018-0255-3","article-title":"Structure of a human synaptic GABAA receptor","volume":"559","author":"Zhu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pbb.2024.173895_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2019.100196","article-title":"Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond","volume":"11","author":"Zorumski","year":"2019","journal-title":"Neurobiol. Stress"},{"key":"10.1016\/j.pbb.2024.173895_bb0985","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0269881115620435","article-title":"NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects","volume":"30","author":"Zuiker","year":"2016","journal-title":"J. Psychopharmacol. (Oxford)"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724001898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305724001898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T13:52:58Z","timestamp":1733233978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305724001898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":199,"alternative-id":["S0091305724001898"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173895","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonsedating anxiolytics","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2024.173895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"173895"}}